Key Takeaways
- Celltrion held over 180 business meetings at the BIO International Convention 2026, its highest since 2010.
- The company showcased its AI-driven technologies and next-generation biologics, attracting over 2,000 visitors to its booth.
- Discussions during the convention focused on strategic collaborations in antibody-drug conjugates and AI-enabled drug development.
Global Expansion at BIO 2026
Celltrion, a South Korean biosimilar firm, is capitalizing on global growth opportunities showcased at the BIO International Convention 2026 in San Diego. This event, recognized as the world’s largest biopharmaceutical and biotechnology gathering, attracted around 20,000 attendees from over 68 countries, including more than 1,600 exhibitors.
During the four-day convention, Celltrion conducted over 180 business meetings, the highest number recorded since its participation began in 2010. These meetings focused on a broad mix of strategic collaborations, particularly in antibody-drug conjugates (ADCs), multispecific antibodies, and technologies for AI-enabled drug development.
The firm introduced several of its innovative technologies, which included AI-powered target discovery, multispecific antibody design, and the Healthcare Intelligence Bank, a data-driven platform aimed at enhancing early-stage drug development. These offerings sparked significant interest among global pharmaceutical and biotechnology companies, leading to discussions about potential partnerships in co-development projects and advancements in manufacturing processes.
Celltrion also reported a surge in booth visitors, with more than 2,000 attendees stopping by, reflecting an expanding interest in the company’s operations beyond its existing biosimilar products. A Celltrion representative highlighted this year’s event as a turning point, indicating that the record number of meetings and visitor interest underscores the company’s growing recognition globally.
The additional focus on AI technology also emphasizes a shift towards innovative drug development strategies. As the conference concluded, Celltrion expressed intentions to continue discussions with potential partners to solidify collaborative opportunities uncovered during the event.
Overall, the convention marked a significant moment for Celltrion as it aims to translate heightened investor and industry interest into concrete business developments, reinforcing its position as a key player in the global biopharmaceutical landscape.
The content above is a summary. For more details, see the source article.